Trident Lifeline Ltd

On 24-Dec, Trident Lifeline Ltd witnessed a significant decline in its share price, falling by 8.78% to close at ₹271.85. This sharp drop contrasts with the broader market’s positive trend, highlighting specific challenges facing the stock despite the company’s strong long-term fundamentals.

Trident Lifeline has shown significant growth over the past four years, with net sales increasing from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operating activities has been negative, indicating challenges despite overall revenue and profitability growth.

Trident Lifeline has shown significant growth in net sales, operating income, and profitability from Mar'22 to Mar'25, with net sales increasing from 21.77 Cr to 86.96 Cr and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operations has declined, with a cash outflow of 10.00 Cr in Mar'25.

As of 11-Nov, Trident Lifeline Ltd's stock price is at Rs 318.00, up 5.74%, and nearing its 52-week high. The stock shows strong performance metrics and increasing institutional interest, indicating a positive outlook despite a recent decline in investor participation.

The next results date for Trident Lifeline is 11 November 2025.

As of 03-Nov, Trident Lifeline Ltd's stock price is Rs 296.50, down 1.17%. Despite a year-to-date increase of 5.89%, the stock has underperformed recently, with mixed signals from moving averages and decreased investor participation, reflecting short-term challenges amid a generally cautious market sentiment.

As of October 30, 2025, Trident Lifeline is considered very expensive with a PE ratio of 23.10 and an EV to EBIT ratio of 24.99, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 13.93%.

As of 30-Oct, Trident Lifeline Ltd's stock price is at Rs 319.00, up 9.98%, and has outperformed the Sensex year-to-date. However, a significant drop in delivery volume raises concerns about the sustainability of this upward trend.

As of October 28, 2025, Trident Lifeline is considered expensive with a PE Ratio of 21.00, indicating it is overvalued compared to peers like Sun Pharma and Divi's Lab, despite a strong 3-year return of 97.65%, its recent performance has lagged behind the Sensex.

As of 28-Oct, Trident Lifeline Ltd's stock price is Rs 290.05, down 2.67%, and has underperformed its sector and the benchmark Sensex. Despite a year-to-date gain of 3.59%, the stock has seen a significant drop in delivery volume and has lagged behind market trends.

As of 17-Oct, Trident Lifeline Ltd's stock price is rising to Rs 308.80, reflecting a 2.93% increase and strong performance relative to its sector and the broader market. The stock has shown consistent gains, positive long-term growth, and increased institutional investment, indicating strong investor confidence.